IPO registrations (S-1, F-1) · Registrants
NYMOX PHARMACEUTICAL CORP
- SEC CIK
- 1018735 · filings on EDGAR ↗
- Registration
- Form F-1, first filed 2000-02-29, last 2000-03-09; 1 initial registration, 1 amendment
- Outcome
- No final prospectus, effectiveness notice or withdrawal within two years of the registration
- Industry (SIC)
- In Vitro & In Vivo Diagnostic Substances 2835
- Business address
- 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT, Quebec Canada, A8 H4M 2V2
- Ticker
- NYMXF (OTC)
- EDGAR entity type
- other
- Insiders and CEO pay
- NYMOX PHARMACEUTICAL CORP on the corporate pages
Offering terms
- Shares offered
- 100,000
- Listing
- Nasdaq under the symbol NYMX
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- SEC filer: NYMOX PHARMACEUTICAL CORP EXACT (CIK (EXACT))
Filings 2
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2000-02-29 | F-1 | F-1 (foreign registration) | NYMOX PHARMACEUTICAL CORP | 0000950123-00-001773 ↗ |
| 2000-03-09 | F-1/A | F-1/A (amendment) | NYMOX PHARMACEUTICAL CORP | 0000950123-00-002110 ↗ |
Prospectus pages read 1
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2000-03-09 | F-1/A | registration statement | 100,000 | - | Nasdaq NYMX | 0 | from the submission text; shares headline | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Robinson James George | Director; Director,TenPercentOwner | 90 | 2015–2023 | ||
| Danielsen Erik | Officer | CFO; Chief Financial Officer | 3 | 2016–2019 | |
| Averback Paul | Director,Officer,TenPercentOwner | CEO | 2 | 2018 | |
| LANHAM RANDALL J | Director,Officer | General Counsel | 1 | 2018 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | NYMOX PHARMACEUTICAL CORP | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry In Vitro & In Vivo Diagnostic Substances, A8 first:
- Anbio Biotechnology 2M
- Asep Medical Holdings Inc. A1
- DNA Testing Centers Corp A6
- MABCURE INC. B9
- ANSYS DIAGNOSTICS INC CA
- Monogram Biosciences, Inc. CA
- ARGONAUT TECHNOLOGIES INC CA
- GENENCOR INTERNATIONAL INC CA
- Intuity Medical, Inc. CA
- Global Wholehealth Partners Corp CA
In other datasets, the same topic (Health) in A8:
- Form D issuer: Acquisition Glacier II Inc. (Form D private offerings)
Interests: In Vitro & In Vivo Diagnostic Substances · Health